June 5th 2025
Valneva’s immunization, Ixchiq, was well tolerated in children ages 1 to 11 years regardless of the dose or previous chikungunya infection.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Will Pennsylvania Proposal Sanction Improper Treatment of Lyme Disease?
June 16th 2017Amesh A. Adalja, MD, FIDSA argues that a bill being considered in the Pennsylvania state legislature will ultimately result in increased antibiotic resistance and will set back the clock for finding appropriate treatments for Lyme disease.
Read More
West Nile Virus: An Early Start to the Season?
June 14th 2017With new human cases of West Nile virus springing up and more states reporting mosquitoes testing positive for the virus, health officials note that this may be an earlier start to the West Nile season than has been seen in past years.
Read More
NIH Funds Studies to Understand Neurological Effects of West Nile Virus
June 7th 2017While health departments around the country continue to report that mosquitoes are testing positive for the West Nile virus, researchers have received a federal grant to study the neurological effects of the virus.
Read More
Past Infectious Disease Outbreaks Can Help Inform Zika Efforts
May 23rd 2017Jean-Paul Gonzalez, MD, PhD, Deputy Director, Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Kansas State University, Adjunct Professor, Kansas State University, explains the importance of vector control in the fight against Zika.
Watch